Digitally Delivered Treatments to Reduce Chronic Low Back Pain
Launched by NEUROSCIENCE RESEARCH AUSTRALIA · May 14, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people with chronic low back pain, which is pain that lasts for a long time and often doesn't have a clear cause. Researchers want to see if using a mobile app that provides pain education and clinical hypnosis can effectively reduce pain and improve daily functioning. This approach will be compared to a standard information pamphlet that follows current guidelines. The trial is designed for adults aged 65 to 74 who are currently seeing a doctor for their back pain and have a moderate level of pain.
To participate, individuals must be experiencing chronic low back pain that can sometimes include pain in the legs, and they should have access to a smartphone or tablet with internet. However, those with specific spinal issues, recent back surgeries, or serious psychiatric conditions that are not being treated will not be eligible. Participants in the study can expect to engage with the app and may also receive support through the trial as they work to manage their pain more effectively. This trial aims to find new ways to help people live better lives despite their chronic pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Experiencing non-specific chronic low back pain (LBP), defined as pain between the 12th rib and the buttock crease.
- • LBP with or without leg pain (in case of leg pain, LBP is worse than leg pain).
- • Currently consulting with a general practitioner for their non-specific chronic LBP across Australia.
- • Mean pain intensity score on the Numeric Rating Scale ≥ 3/10 in the past week.
- • A score of at least moderate on question 8 of the physical functioning component of the SF-36 questionnaire.
- • Access to a mobile device with minimal requirements to download the study app (300MB).
- • An internet connection to access the mobile app functionalities.
- • Able to understand English via reading and audio materials.
- Exclusion Criteria:
- • Known or suspected specific spinal (e.g., radiculopathy, fracture) or specific non-spinal non- (e.g., tumour, infection) pathology.
- • Less than six months post-spinal surgery.
- • Scheduled for major surgery during the program or the follow-up period.
- • Known or suspected serious psychiatric condition not being treated by a health professional that would impact adherence to the trial activities.
- • Known or suspected sight or hearing problems that would limit access to the intervention components (reading and listening using headphones).
About Neuroscience Research Australia
Neuroscience Research Australia (NeuRA) is a leading independent medical research institute dedicated to advancing our understanding of the brain and nervous system. Located in Sydney, NeuRA focuses on a broad range of neurological and psychological disorders, aiming to translate scientific discoveries into real-world applications that improve patient outcomes. The institute conducts innovative clinical trials and research studies, leveraging cutting-edge technologies and interdisciplinary collaboration to drive breakthroughs in diagnosis, treatment, and prevention. With a commitment to excellence in research and a strong emphasis on community engagement, NeuRA strives to enhance the quality of life for individuals affected by neurological conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Randwick, New South Wales, Australia
Patients applied
Trial Officials
James H McAuley, PhD
Principal Investigator
Neuroscience Research Australia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported